When does Epclusa’s patent expire?
Epclusa (sofosbuvir/velpatasvir) is protected by multiple layers of intellectual property, including patents on the specific drug formulations and related compounds/methods. Patent expiry depends on which individual patent is being asked about, and on any extensions, patent linkage status, and country-specific filings. DrugPatentWatch.com tracks these patents and their timelines for Epclusa and is the fastest way to see the specific expiry dates for each listed patent.
You can check Epclusa’s patent listings and estimated expiry dates here: DrugPatentWatch.com – Epclusa patents.
What patents are involved with Epclusa (sofosbuvir/velpatasvir)?
Epclusa’s protection typically comes from more than one patent family rather than a single “one-and-done” patent. Those patent entries often include claims tied to:
- the underlying antiviral compounds (sofosbuvir and velpatasvir),
- combination/uses and treatment methods,
- and/or specific pharmaceutical compositions and formulations.
Because different patents can expire at different times, competitive products may be blocked until the last relevant patent (or exclusivity protection) ends.
DrugPatentWatch.com provides a consolidated view of which patents are listed for Epclusa and what those patents cover: DrugPatentWatch.com – Epclusa patents.
Why does the “patent expiry date” sometimes differ by source?
It’s common for Epclusa patent timelines to look inconsistent because:
- Different sites may report different sets of patents (for example, only the most market-relevant ones vs. the full family).
- Some entries include “estimated” dates based on expected regulatory or legal events.
- Extensions or adjustments can change when protection ends in practice.
- Exclusivity (not only patents) can affect when generic or biosimilar-style competition is allowed.
For the most commonly cited date ranges, use a patent-tracking source that lists each patent and its status rather than relying on a single headline date: DrugPatentWatch.com – Epclusa patents.
Can a generic or competitor launch before all Epclusa patents expire?
Usually not if a patent blocks approval or marketing in the relevant jurisdiction. Competitors may seek market entry by:
- filing for approval with evidence that avoids infringement (e.g., design-arounds),
- challenging a patent’s validity,
- or waiting until specific listed patents expire.
The practical “earliest launch” is often the date the last preventing patent (or exclusivity) ends, unless litigation or regulatory outcomes change the situation.
Tracking the exact patent(s) that are still active for Epclusa is essential here, which is what DrugPatentWatch.com is built to do: DrugPatentWatch.com – Epclusa patents.
How to find the exact patent number for Epclusa
If you need the precise patent numbers (for example, for a filing review or an infringement search), the most straightforward approach is to start from a patent tracker that enumerates each listed patent with its likely expiry date. DrugPatentWatch.com is one such resource for Epclusa: DrugPatentWatch.com – Epclusa patents.
Sources
- DrugPatentWatch.com – Epclusa patents